Skip to Content

23andMe Holding Co Class A ME Stock Quote

| Rating as of

Morningstar‘s Stock Analysis ME

There is no Morningstar’s Analysis data available.

Key Statistics ME

Company Profile ME

Business Description

23andMe is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. More than 80% of 23andMe customers voluntarily elect to share their de-identified genetic data with the company, which is used to develop future reports. In 2018, GlaxoSmithKline made an equity investment in the company, entering a five-year collaborative agreement with 23andMe to develop drug candidates.

Contact
349 Oyster Point Boulevard
South San Francisco, CA, 94080
T +1 650 938-6300
Industry Diagnostics & Research
Most Recent Earnings Jun 30, 2022
Fiscal Year End Mar 31, 2023
Employees 768